NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin

Cancer Science

Volumn 104, Issue 7, 2013, Pages 920-925

  Takahashi, Amane ^a,b,c   Yamamoto, Yoshiyuki ^a,c   Yasunaga, Masahiro ^a   Koga, Yoshikatsu ^a   Kuroda, Jun Ichiro ^a   Takigahira, Misato ^a   Harada, Mitsunori ^d   Saito, Hiroyuki ^d   Hayashi, Tatsuyuki ^d   Kato, Yasuki ^d   Kinoshita, Taira ^b   Ohkohchi, Nobuhiro ^c   Hyodo, Ichinosuke ^c   Matsumura, Yasuhiro ^a  

^a Research Center for Innovative Oncology   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d NanoCarrier Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; EPIRUBICIN; NC 6300; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART FUNCTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; EPIRUBICIN; FEMALE; HEART; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MICELLES; PROTEINS; RANDOM ALLOCATION; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880760316     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12153     Document Type: Article

References (22)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
2. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
3. Hung H. Treatment modalities for hepatocellular carcinoma. Curr Cancer Drug Targets 2005; 5: 131-8.
4. Johnson PJ. Hepatocellular carcinoma: is current therapy really altering outcome? Gut 2002; 51: 459-62.
5. Takayama T, Makuuchi M, Hirohashi S et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 1998; 28: 1241-6.
6. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
7. Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 2004; 40: 1474-84.
8. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
9. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
10. Biganzoli L. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 2002; 20: 3114-21.
11. Martin M, Rodriguez-Lescure A, Ruiz A et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 2008; 100: 805-14.
12. Roche H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24: 5664-71.
13. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
14. Bristow MR, Billingham ME, Mason JW et al. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978; 62: 873-9.
15. Lefrak EA, Pitha J, Rosenheim S et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32: 302-14.
16. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008; 94: 525-33.
17. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339: 900-5.
18. de Azambuja E, Paesmans M, Beauduin M et al. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study. J Clin Oncol 2009; 27: 720-5.
19. Salvatorelli E, Menna P, Lusini M et al. Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart. J Pharmacol Exp Ther 2009; 329: 175-84.
20. Innocenti F, Iyer L, Ramirez J et al. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 2001; 29: 686-92.
21. Harada M, Bobe I, Saito H et al. Improved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300. Cancer Sci 2011; 102: 192-9.
22. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-92.